Modified Virus Helps Immune System Fight Deadly Brain Cancer

A single injection of a modified virus is helping the immune system finally reach one of the most stubborn cancers known to medicine.

Researchers at Mass General Brigham and Dana-Farber Cancer Institute discovered that injecting a specially engineered herpes virus into glioblastoma tumors recruits powerful immune cells that can hunt down and destroy cancer. The breakthrough addresses a problem that has stumped doctors for decades: glioblastoma is a "cold" tumor, meaning immune cells can't penetrate it to fight back.

The modified virus works like a double agent. It infects a glioblastoma cell, kills it, then copies itself to attack another cancer cell. As it spreads, it also triggers an immune response that brings T cells deep into the tumor.

In a clinical trial of 41 patients with recurring glioblastoma, this approach extended survival beyond what doctors typically see. Patients who already had antibodies against the virus from past infections saw especially strong results. Importantly, the virus only replicates in cancer cells and leaves healthy brain tissue alone.

The team's analysis revealed something even more exciting. The therapy didn't just bring T cells into the tumors temporarily. These cancer-fighting cells stayed there long term, continuing their work. When researchers looked at tumor samples, they found that patients with T cells closer to dying cancer cells survived longer.

"We show that increased infiltration of T cells that are attacking tumor cells translates into a therapeutic benefit for patients with glioblastoma," said Dr. E. Antonio Chiocca, who developed the virus and led the study published in Cell.

The Bright Side

This breakthrough could finally crack open immunotherapy for brain cancer patients. While immunotherapies have transformed treatment for melanoma and other cancers, they've never worked for glioblastoma because the immune system couldn't reach these tumors. Now doctors have a way to guide those powerful immune cells exactly where they need to go.

The approach also builds on immune cells already present in the brain. Rather than replacing the immune system, the virus amplifies what's already there, expanding pre-existing T cells and keeping them active against the cancer.

Standard treatment for glioblastoma hasn't changed in 20 years, leaving patients and families with few options. This research opens a new path forward, combining the virus's direct cancer-killing ability with the immune system's long-term surveillance.

After decades of frustration, scientists have found a key that unlocks the door for our own immune defenses to reach brain tumors.